Analysts think TGTX stock price could increase by 40%
Dec 25, 2024, 12:26 PM
-9.70%
What does TGTX do
TG Therapeutics, based in Morrisville, North Carolina, develops treatments for B-cell malignancies and autoimmune diseases, with key candidates including Ublituximab, TG-1701, and TG-1801. The company employs 284 people and explores partnership opportunities for additional products.
10 analysts think TGTX stock price will increase by 39.55%. The current median analyst target is $44.88 compared to a current stock price of $32.16. The lowest analysts target is $9.09 and the highest analyst target is $57.75.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
